BioCrea GmbH
BioCrea GmbH: BioCrea to Present at BioTrinity 2014 on 13 May 2014
BioCrea GmbH / Key word(s): Miscellaneous Radebeul, Germany, May 09, 2014 – BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist, today announced that Chief Executive Officer, Dr. Tom Kronbach, will present at BioTrinity 2014, Europe’s leading Biopartnering and Investment Conference, to be held on 12-14 May in London. Tom Kronbach will be presenting on May 13, 2014 at 13:50 BST in the Alsace Room, Mezzanine Floor, Novotel London West, UK. “This is a wonderful opportunity for BioCrea to present its lead programs and novel discovery platforms to over 30 major pharmaceutical companies,” said Dr. Tom Kronbach, CEO of BioCrea. “In partnering terms, we will talk about our two unique proprietary small molecule programs: Long-term acting GABAA positive allosteric modulators (LT GABAA PAMs) to treat epilepsy plus autism; and NMDA receptor 2B (NR2B) negative allosteric modulators (NAMs) to treat depression. Both programs are expected to reach the IND-enabling study phase later this year.” Founded and produced by OBN, BioTrinity has become the “must attend” life sciences conference for emerging European companies, investors and partners. The conference is now in its eighth year. BioTrinity has grown rapidly over recent years, and is now located in London to accommodate increased interest. More than 1000 senior executives and decision makers from emerging and established companies across the life sciences sector and investment firms are expected to meet one-on-one, attend panel discussions and workshops, or browse the company showcases, seeking out their next deals. Dr. Tom Kronbach
End of Corporate News 09.05.2014 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
267460 09.05.2014 |